Among the several p53 drugs, MD Anderson as all should know has been working with Kevetrin, so it's very possible the reference to a possible drug currently in phase 1 is that very same K.
Wouldn't it also be great if part of the experimental Phase 1 extension is to test this same potential immune biomarker associated with p53?!?
News 
Market Data 
Discover 
